Refine
Year of publication
- 2021 (1)
Document Type
- Doctoral Thesis (1)
Language
- English (1)
Has Fulltext
- yes (1)
Is part of the Bibliography
- no (1)
Institute
- Medizin (1)
The postthrombotic syndrome (PTS) is beside the venous thromboembolism (VTE) recurrence and chronic thromboembolic pulmonary hypertension (CTEPH) a long-term adverse outcome and chronic complication of deep vein thrombosis (DVT) in the lower extremities and can occur in up to 20–50% of patients within 2 years after DVT. The prevalence of PTS in the adult population is expected to increase due to the growing incidence of VTE in the elderly. Although not life threatening it can impose significant morbidity and can be associated with a negative impact on quality of life associated with disease severity. From an economic point of view, PTS is an important predictor of increased health care costs after VTE.
Factors potentially related to the development of the PTS are older age, obesity, a history of previous ipsilateral DVT, iliofemoral location of the current thrombosis, failure to promptly recover from the acute symptoms and insufficient quality of oral anticoagulant therapy. Furthermore, it is known that the severity of PTS correlates with the location of the DVT, the more proximal the more severe.
PTS induces a range of symptoms and clinical signs, which can be assessed in different scales. The Villalta scale is one of the most suitable scales for defining the presence and severity of subjective symptoms and physical signs of PTS.
In the last century, various therapeutic strategies have been developed to prevent mortality due to VTE or long-term morbidity due to PTS.
Conservative treatment today consists of anticoagulation - usually using direct oral anticoagulants - and compression therapy. One of the first invasive treatments with the aim of thrombus removal was surgical venous thrombectomy by Läwen in 1938. Mahorner and Fontaine improved the technique in the 1950s combining it with a course of anticoagulant treatment to prevent rethrombosis and PTS.
Mechanical thrombectomy by the use of Fogarty balloons, which started in 1963, or the creation of a transient arteriovenous fistula, performed since 1974, are now no longer recommended due to the high invasiveness, risk of fatal intraoperative embolism and a high rethrombosis rate.
In current practice, early thrombus removal mainly relies on the use of catheter-directed pharmacologic thrombolytic therapy. Another approach currently is the endovenous, device-driven thrombectomy and stenting in case of venous obstruction. There is an ongoing broad discussion as to whether these invasive therapies should be offered to patients with iliofemoral thrombosis (IFT), which remains controversial.
IFT, the major target for endovenous thrombectomy respectively pharmacologic thrombolytic therapy, is not enough represented in current literature because the used definition of proximal DVT does not necessarily include the iliac veins. In consequence, it may not be representative enough concerning questions like prevalence and severity of PTS or the effects on quality of life.
The present registry – the Iliaca-PTS registry – addresses exactly these patients and tries to answer these questions. The data of 85 patients who had suffered an IFT in the past were evaluated in the prospective registry documenting the severity of PTS, the occurrence of iliac vein compression syndrome in left-sided IFT and quality of life. A significant predictor for the development of severe PTS or venous claudication in our patient population is a high BMI.
The results of this registry show that IFT is frequently observed and only ten percent develop a moderate or severe PTS respectively venous claudication. In conclusion, the conservative treatment strategy with optimal effective anticoagulant therapy can lead to a low incidence of PTS and a high quality of life.